Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)

NCT02160054 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 289

Last updated 2024-10-21

No results posted yet for this study

Summary

To evaluate the safety and efficacy of Graceptor ® in patients with kidney transplantation when converted from cyclosporine

Conditions

  • the Maintenance Phase After Kidney Transplantation

Interventions

DRUG

Graceptor®

oral

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Astellas Pharma Inc

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-15
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02160054 on ClinicalTrials.gov